PDGFRA is also a validated target in other solid tumors, such as gastrointestinal stromal tumor (GIST), where PDGFRA‐D842V mutations confer high sensitivity to avapritinib (objective response rate (ORR) up to 91%) [56]. Here, PDGFRA is linked to gastrointestinal stromal tumor.